Lytix Biopharma

Less than 1K followers

LYTIX

Euronext Growth Oslo

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

Lytix Biopharma is a clinical-stage biotechnology company developing cancer immunotherapies. The company's technology is based on research into antimicrobial peptides, a defense against pathogens. Lytix Biopharma's lead product, LTX-315, is an oncolytic peptide with the aim of personalizing immunotherapy. The company conducts its research and operations in Oslo, Norway.

Market cap

-

Turnover

-

Revenue

11.13M

EBIT %

-861.64 %

P/E

-

Dividend yield-%

-

All

Press releases

ShowingAll content types

Press release11/19/2025, 7:23 AM

Redeye: Lytix Biopharma (Q3 Review) - Positive Clinical Readouts

Lytix Biopharma

Regulatory press release11/18/2025, 6:00 AM

Lytix Biopharma AS: Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy

Lytix Biopharma

Regulatory press release11/14/2025, 6:05 AM

Lytix Biopharma AS: Lytix Biopharma: Invitation to Q3 2025 Results Presentation

Lytix Biopharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release11/11/2025, 2:27 PM

BioStock: Lytix Biopharma’s oncolytic immunotherapy ruxotemitide shows strong phase II data

Lytix Biopharma

Regulatory press release11/11/2025, 6:00 AM

Lytix Biopharma AS: Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital

Lytix Biopharma

Regulatory press release11/11/2025, 6:00 AM

LYTIX: Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital

Lytix Biopharma

Regulatory press release11/10/2025, 6:00 AM

Lytix Biopharma AS: New Phase II Study Data from Lytix Biopharma's Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide

Lytix Biopharma

Regulatory press release10/10/2025, 9:46 AM

LYTIX: Financial calendar

Lytix Biopharma

Regulatory press release10/8/2025, 5:05 AM

Lytix Biopharma AS: Lytix Biopharma's licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025

Lytix Biopharma

Regulatory press release9/1/2025, 5:55 PM

Lytix Biopharma AS: Grant of share options to management and key personnel

Lytix Biopharma

Press release8/29/2025, 10:51 AM

Redeye: Lytix Biopharma Q2 2025 - Extended Update

Lytix Biopharma

Regulatory press release8/28/2025, 5:07 AM

Lytix Biopharma AS: Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization

Lytix Biopharma

Regulatory press release8/21/2025, 12:08 PM

Lytix Biopharma AS: Lytix Biopharma: Invitation to Q2 2025 Results Presentation

Lytix Biopharma

Press release5/19/2025, 11:16 AM

Redeye: Lytix Biopharma Q1 2025 - Progress in NeoLIPA but Financial Weakness for Verrica

Lytix Biopharma

Regulatory press release5/15/2025, 5:05 AM

Lytix Biopharma AS: Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress

Lytix Biopharma

Regulatory press release5/9/2025, 5:10 AM

Lytix Biopharma AS: Lytix Biopharma: Invitation to Q1 2025 Results Presentation

Lytix Biopharma

Regulatory press release4/29/2025, 12:27 PM

Lytix Biopharma AS reshuffled its Board after the Ordinary General Meeting

Lytix Biopharma

Regulatory press release4/22/2025, 7:33 PM

Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair

Lytix Biopharma

Regulatory press release4/10/2025, 5:20 AM

Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025

Lytix Biopharma

Regulatory press release4/10/2025, 5:05 AM

Lytix Biopharma AS: Annual Report for 2024

Lytix Biopharma

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.